Even before the green light from the health authorities, the United States ordered from the Pfizer laboratory 10 million treatments of its anti-Covid pill for 5.29 billion dollars, announced the pharmaceutical giant, this Thursday.
The group, which already markets a vaccine against the virus in collaboration with BioNTech, filed at the beginning of the week with the American Medicines Agency (FDA) an emergency authorization request for this highly anticipated treatment because it can easily be taken at home in the first few days after the onset of symptoms in case of infection.
Discussions with other states
This antiviral treatment, which will be marketed as Paxlovid, has been shown to be 89% effective against hospitalizations and death in clinical trials, when taken within three days of symptom onset.
These trials were conducted by the company on people at high risk of developing a severe case of Covid-19.
Antivirals work by decreasing the ability of a virus to replicate, thereby slowing down the disease.
They represent a key complement to vaccines to protect against Covid-19.
The order from Washington provides for the delivery of 10 million treatments this year and in 2022. "The price paid by the US government reflects the high volume of treatments purchased," said Pfizer in the press release, indicating that it has engaged in discussions with others. States.
A voluntary license agreement
The group is already benefiting greatly from sales of its anti-Covid vaccine, which allowed it to double its turnover in the third quarter, to $ 24.1 billion, and to multiply its net profit by five over the period, to $ 8.15 billion.
The American laboratory Merck has also developed an antiviral treatment, molnupiravir, authorized in early November in a first country, the United Kingdom.
An FDA committee is due to meet on November 30 to decide on the application for authorization of Merck's treatment in the United States.
Washington has already purchased 3.1 million treatments from Merck.
Pfizer also agreed on Tuesday to enter into a voluntary licensing agreement with the Medicines Patent Pool (MPP), created by Unitaid, which will allow generic manufacturers to produce the drug for supply to 95 middle-income countries. or less representing about 53% of the world's population.
Merck has entered into a similar pact with the MPP for its own oral anti-Covid.
Health
Coronavirus: How does Paxlovid, Pfizer's anti-Covid pill work?
World
Coronavirus: Pfizer projects $ 36 billion in annual revenue for its vaccine
Video
Pfizer-BioNTech
Medication
United States
Covid 19
Coronavirus
World
0 comment
0 share
Share on Messenger
Share on Facebook
Share on twitter
Share on Flipboard
Share on Pinterest
Share on Linkedin
Send by Mail
To safeguard
A fault ?
To print